Importance of the trial results & challenges, page-4

Excellent post Noda - I was about to make some similar comments, but you have done it far more eloquently.

I haven't re-visited the phase 2 trial results but I don't recall the point that trofinetide "targets mechanisims underlying the disorder rather than a symptomatic medication".

If this applies to the whole of the autism spectrum, then ramifications are almost mind-boggling (no pun intended).

My original reading of these results was that they really didn't tell us much that we didn't already know. I'm delighted that now appears not to be the case, however trading over the next few weeks will likely give a pretty good pointer as to how significant this point might be.